Autolus Therapeutics (AUTL) news
Recent news
Autolus Therapeutics - Q2 2026 net product revenue $45.70 mln vs $20.90 mln in Q2 2025
Autolus Therapeutics (Nasdaq: AUTL) reported preliminary second-quarter 2026 net product revenue of $45.7 million for AUCATZYL (obecabtagene autoleucel; obe-cel), a significant increase from $20.9 million in the same period in 2025. The year-over-year growth reflects a 119% increase in revenue and…
AInvest Wire · Aug 11, 2026Autolus Therapeutics - increases FY2026 net product revenue guidance to $140-$150 mln
Autolus Therapeutics (Nasdaq: AUTL) has raised its full-year 2026 net product revenue guidance for AUCATZYL to a range of $140–$150 million , up from the previous range of $120–$135 million. This upward revision follows preliminary second-quarter 2026 net product revenue of approximately $45…
AInvest Wire · Aug 11, 2026Autolus Therapeutics sees 2026 net product revenue $140M-$150M
AInvest Wire · Aug 11, 2026Autolus Therapeutics 2Q loss/share 15c
AInvest Wire · Aug 11, 2026Autolus: Funding will allow co. to deliver on key priorities
Autolus Therapeutics has secured significant funding to support its strategic priorities and regulatory milestones. In February 2024, the company announced a strategic collaboration and equity investment with BioNTech, generating $250 million upfront and $200 million through a private placement of…
AInvest Wire · Aug 3, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.